(Q34294838)

1 August 2017

1 reference

title

Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy (English)

1 reference

stem cell transplantation

1 August 2017

0 references

1 reference

M Boeckh

1

1 reference

PubMed ID

11428987

1 August 2017

language of work or name

1 reference

1 September 1999

1 reference

Transplant Infectious Disease

1 August 2017

1 reference

1 August 2017

1

1 reference

1 August 2017

3

1 reference

1 August 2017

165-178

1 reference

Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses

1 August 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Cytomegalovirus (CMV)-Specific Intravenous Immunoglobulin for the Prevention of Primary CMV Infection and Disease after Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Treatment of Interstitial Pneumonitis Due to Cytomegalovirus with Ganciclovir and Intravenous Immune Globulin: Experience of European Bone Marrow Transplant Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Prevalence of Resistance in Patients Receiving Ganciclovir for Serious Cytomegalovirus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

Quantitation of cytomegalovirus: methodologic aspects and clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Cytomegalovirus disease occurring before engraftment in marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Recognition and rapid diagnosis of upper gastrointestinal cytomegalovirus infection in marrow transplant recipients. A comparison of seven virologic methods.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

1 reference

7 January 2021

Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Circulating cytomegalovirus (CMV)-infected endothelial cells in marrow transplant patients with CMV disease and CMV infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infecti

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recov

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Cli

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010305.X

7 January 2021

10.1034/J.1399-3062.1999.010305.X

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11428987